Oculis (OCS) Stock Price, News & Analysis

Company Overview

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery. The company is also developing other investigational candidates, including OCS-02, a topical anti-inflammatory therapy for conditions such as dry eye disease, and OCS-05, a potential neuroprotective treatment for disorders affecting the optic nerve and retina.

Founded in Europe, Oculis is headquartered in Zug, Switzerland, and has developed an international operating presence that includes activities in Europe and the United States. The company’s programs are intended for global markets, subject to clinical development results and regulatory approval. Oculis is led by Chief Executive Officer Riad Sherif, M.D.

Key Stats

• Today's Range: $8.81 to $9.26
• 50-Day Range: $9.06 to $13.57
• 52-Week Range: $8.81 to $34.47
• Volume: 222,843 shs
• Average Volume: 429,098 shs
• Market Capitalization: $512.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.44
• Consensus Rating: Moderate Buy

Oculis Stock Analysis - MarketRank™

Oculis scored higher than 45% of companies evaluated by MarketBeat, and ranked 653rd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oculis has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oculis has a consensus price target of $39.44, representing about 338.1% upside from its current price of $9.00.

Amount of Analyst Coverage

Oculis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oculis are expected to decrease in the coming year, from ($2.01) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oculis is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oculis is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oculis has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.68% of the float of Oculis has been sold short.

Short Interest Ratio / Days to Cover

Oculis has a short interest ratio ("days to cover") of 9.91.

Change versus previous month

Short interest in Oculis has recently increased by 4.14%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oculis does not currently pay a dividend.

Dividend Growth

Oculis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.32

News Sentiment

Oculis has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Oculis this week, compared to 6 articles on an average week.

Search Interest

5 people have searched for OCS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oculis insiders have not sold or bought any company stock.

Percentage Held by Institutions

22.30% of the stock of Oculis is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OCS
• CIK: 1953530
• Web: www.oculis.com
• Phone: 41-21-711-3970
• Fax: N/A
• Employees: 60
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Oculis: $39.44
• High Price Target: $55.00
• Low Price Target: $20.00
• Potential Upside/Downside: +341.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.44 million
• Net Margins: -6,777.18%
• Pretax Margin: -6,956.07%
• Return on Equity: -42.61%
• Return on Assets: -35.23%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.35
• Quick Ratio: 8.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.08 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 57,984,000
• Free Float: N/A
• Market Cap: $517.80 million
• Optionable: Not Optionable
• Beta: 0.52